BostonGene to Showcase AI-Powered Cancer Research at AACR 2026

Got story updates? Submit your updates here. ›

BostonGene, a developer of an AI-powered platform for cancer research, announced that it will present 13 abstracts at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026. The abstracts will showcase how the company's AI foundation model is being used to accelerate drug discovery, optimize patient stratification, and de-risk clinical development for new cancer treatments.

Why it matters

As the pharmaceutical industry increasingly turns to AI and machine learning to drive innovation, BostonGene's presentations at AACR 2026 will provide valuable insights into how this technology can be leveraged to streamline the complex and costly cancer drug development process. The company's AI platform aims to uncover new insights from vast amounts of tumor and immune system data, potentially leading to more effective therapies for patients.

The details

BostonGene's AI foundation model is an omnimodal system that can analyze a wide range of data types, including genomic, transcriptomic, proteomic, and imaging data, to gain a comprehensive understanding of tumor biology and the tumor microenvironment. The 13 abstracts to be presented at AACR 2026 will demonstrate how this technology can be applied to accelerate drug discovery, optimize patient selection for clinical trials, and de-risk the overall drug development process.

• The AACR Annual Meeting 2026 will take place from April 11-15, 2026.

What’s next

The presentations at AACR 2026 will provide further details on how BostonGene's AI platform is being used to advance cancer research and drug development.